2 Top Stocks to Profit Off the AI and Cryptocurrency Booms
Artificial intelligence (AI) and cryptocurrency are two high-growth markets that offer promising return potential. Investing in the right stocks could pay off handsomely in the coming years. Here are two stocks that could deliver.
1. Advanced Micro Devices
AI is expected to increase the global economy by $15.7 trillion by 2030, according to PwC. This is a huge opportunity for one of the leading chipmakers, Advanced Micro Devices (NASDAQ: AMD).
AMD stock pulled back sharply to start the year, but it has begun to recover. The business is set to supply a leading AI company with its new chips, which could benefit the stock.
The last few years have seen a lot of chip investment go toward AI training, which is the process of feeding large data sets to AI models to make them smarter. Nvidia capitalized on the demand for AI training with its graphics processing units (GPUs).
While AMD was late to the party, its first data center GPU, the MI300, was launched in late 2023 and raked in $5 billion of revenue last year. Management still sees a $500 billion opportunity as it launches new GPUs designed for AI inferencing, which takes a model to the next level by teaching it to make decisions on its own from new data. This is expected to be a huge market, and AMD has positioned its new chip lineup to take advantage of the opportunity.
The company reported accelerating revenue growth last quarter, with data center revenue up 57% year over year. It gained business from one of the leading AI model developers that is using its Instinct GPUs for daily inferencing needs.
AMD will launch its Instinct MI400 GPU in 2026, and OpenAI just announced plans to use the chip. This is a huge win and signals growing momentum for its data center business. Demand for AI inferencing hardware is expected to grow from $106 billion in 2025 to $255 billion by 2030, according to MarketsandMarkets. AMD is well positioned for this opportunity, making the recent dip a great buying opportunity.
2. Coinbase Global
The cryptocurrency market was worth more than $3 trillion as of June 12, yet only 7% of the global population uses cryptocurrency, according to the crypto exchange Kraken. As interest in digital currencies continues to grow, Coinbase Global (NASDAQ: COIN) could grow along with it.
Coinbase is a leading cryptocurrency exchange with more than $300 billion in assets on the platform. It saw a sharp increase in revenue last year as trading volumes soared, which has sent the stock up nearly 600% since 2022.
But the shares have been volatile over the last few years, reflecting the downturn in the markets a few years ago. The risk for holding the stock is when markets decline, trading volumes drop, which depresses revenue.
However, Coinbase has a lot of opportunity to attract more assets to its platform. It is expanding the number of trading products and services to appeal to institutional investors, which make up the majority of its trading volume. Its push into crypto options and stablecoins, as well as improvements to its trading infrastructure are positioning it to attract more customers.
As demand for digital assets continues to grow, the exchange should see increasing trading volumes and revenue. And there are strong signals pointing to rising demand for cryptocurrencies over the long term.
A recent report from Coinbase showed that 60% of Fortune 500 executives are working on blockchain initiatives, which serve as the digital ledger for crypto transactions. Another strong signal supporting the long-term future of the market was President Donald Trump's recent executive order to establish a Strategic Bitcoin Reserve for the U.S. government.
These are bullish indicators for crypto and Coinbase. There are a lot of places to buy and sell cryptocurrency, but Coinbase is on a mission to become not just a leading crypto exchange but also a leading financial services platform. This makes the stock a great way to benefit from this booming market.
Should you invest $1,000 in Advanced Micro Devices right now?
Before you buy stock in Advanced Micro Devices, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Advanced Micro Devices wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!*
Now, it's worth noting Stock Advisor 's total average return is988% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of June 9, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
an hour ago
- National Post
Trump family company announces next venture: a mobile phone company
NEW YORK — If Trump watches or sneakers or bibles aren't your thing, the family business just added another product to show your support for the U.S. president: mobile phones. Article content The Trump company announced Monday a new business, Trump Mobile, that will offer cell service in a licensing deal and sell gold phones by the summer. It's the latest in a string of new schemes struck despite mounting ethical concerns that the U.S. president is profiting off his position and could manipulate public policy for personal gain. Article content Article content Article content Eric Trump, the president's son running The Trump Organization in his absence, suggested the pitch is patriotism, emphasizing that the phones will be built in the U.S. and the phone service will maintain a call center in the country as well. Article content Article content The announcement follows several real estate deals for towers and resorts in the Middle East, including a golf development in Qatar announced in April. A $1.5 billion partnership to build golf courses, hotels and real estate projects in Vietnam was approved last month, though the deal was in the works before Trump was elected. Article content Trump has already used the main regulatory agency that will oversee Trump Mobile in personal disputes. The Federal Communications Commission has launched investigations of media outlets Trump dislikes and, in some cases, is personally suing. And the president himself last month criticized cell phone maker Apple, now a big business rival, because it planned to make most of its U.S. iPhones in India, threatening to slap a 25% tariff on the devices. Article content Article content Eric Trump said that consumers deserve a phone that aligns with their values. Article content 'Hard-working Americans deserve a wireless service that's affordable, reflects their values, and delivers reliable quality they can count on,' he said in a statement. Article content The Trump phone deal comes as a mandatory financial disclosure report just filed with the government shows the president has moved fast in the last year to profit off his celebrity, taking in $3 million in revenue from selling 'Save America' coffee table books, $2.8 million from Trump watches and $2.5 million from Trump branded sneakers and fragrances. Article content The Trump Organization on Monday said the new, gold-colored phone available for $499 in August, called the T1 Phone, won't be designed or made by Trump Mobile, but by another company.
Globe and Mail
an hour ago
- Globe and Mail
Anaplastic Thyroid Cancer Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 8+ Companies and 8+ Therapies
DelveInsight's, 'Anaplastic Thyroid Cancer Pipeline Insight 2025,' report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Anaplastic Thyroid Cancer pipeline landscape. It covers the Anaplastic Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Anaplastic Thyroid Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Anaplastic Thyroid Cancer Pipeline. Dive into DelveInsight's comprehensive report today! @ Anaplastic Thyroid Cancer Pipeline Outlook Key Takeaways from the Anaplastic Thyroid Cancer Pipeline Report In June 2025, M.D. Anderson Cancer Center announced a phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 (LN-145) or LN-145-S1 works in treating patients with ovarian cancer, triple negative breast cancer (TNBC), anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment (refractory) or that has come back (relapsed). DelveInsight's Anaplastic Thyroid Cancer Pipeline report depicts a robust space with 8+ active players working to develop 8+ pipeline therapies for Anaplastic Thyroid Cancer treatment. The leading Anaplastic Thyroid Cancer Companies such as Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others. Promising Anaplastic Thyroid Cancer Pipeline Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar,BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208 and others. Stay ahead with the most recent pipeline outlook for Anaplastic Thyroid Cancer. Get insights into clinical trials, emerging therapies, and leading companies with Anaplastic Thyroid Cancer @ Anaplastic Thyroid Cancer Treatment Drugs Anaplastic Thyroid Cancer Emerging Drugs Profile Sapanisertib: Takeda Sapanisertib is a dual TORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells. These mutations are found in a considerable sub-population of patients across multiple solid tumor types. Sapanisertib has demonstrated promising single-agent activity in patients with relapsed/refractory NRF2-mutated squamous non-small cell lung cancer (NSCLC) and exhibits differential anti-tumor activity compared to rapalog inhibitors of TORC1 in NRF2-mutant squamous NSCLC in vivo models. HLX208: Shanghai Henlius Biotech BRAF V600E small-molecule inhibitor can be potentially used in the treatment of various solid tumors. HLX208 may be combined with the Company's proprietary EGFR or PD-1 targeted antibodies to enhance a high-quality, innovative and differentiated product portfolio for the treatment of various cancer types. The Anaplastic Thyroid Cancer Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Anaplastic Thyroid Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Anaplastic Thyroid Cancer Treatment. Anaplastic Thyroid Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Anaplastic Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Anaplastic Thyroid Cancer market Explore groundbreaking therapies and clinical trials in the Anaplastic Thyroid Cancer Pipeline. Access DelveInsight's detailed report now! @ New Anaplastic Thyroid Cancer Drugs Anaplastic Thyroid Cancer Companies Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others. Anaplastic Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous Intravenous/ Subcutaneous NA Oral Oral/intranasal/subcutaneous Parenteral Subcutaneous Anaplastic Thyroid Cancer Products have been categorized under various Molecule types such as Antibody Antisense oligonucleotides Immunotherapy Monoclonal antibody Peptides Protein Recombinant protein Small molecule Stem Cell Vaccine Unveil the future of Anaplastic Thyroid Cancer Treatment. Learn about new drugs, Anaplastic Thyroid Cancer Pipeline developments, and key companies with DelveInsight's expert analysis @ Anaplastic Thyroid Cancer Market Drivers and Barriers Scope of the Anaplastic Thyroid Cancer Pipeline Report Coverage- Global Anaplastic Thyroid Cancer Companies- Takeda, Shanghai Henlius Biotech, Taizhou Hanzhong Pharmaceuticals, AffyImmune Therapeutics, Inc., Merck & Co, Iovance Biotherapeutics, Inc., Codiak BioSciences, Hutchison Medipharma Limited, Bristol-Myers Squibb and others. Anaplastic Thyroid Cancer Pipeline Therapies- Pembrolizumab, Lenvatinib, Nivolumab, Sorafenib (Nexavar, BAY43-9006), dabrafenib/trametinib, Sacituzumab govitecan, MLN0128, Pembrolizumab (Keytruda), efatutazone, HLX208 and others. Anaplastic Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Anaplastic Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Anaplastic Thyroid Cancer Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Anaplastic Thyroid Cancer Companies, Key Products and Unmet Needs Table of Contents Introduction Executive Summary Anaplastic Thyroid Cancer: Overview Pipeline Therapeutics Therapeutic Assessment Anaplastic Thyroid Cancer – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug name: Company name Drug profiles in the detailed report….. Mid Stage Products (Phase II) Sapanisertib: Takeda Drug profiles in the detailed report….. Early Stage Products (Phase I) AIC100: AffyImmune Therapeutics Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Anaplastic Thyroid Cancer Key Companies Anaplastic Thyroid Cancer Key Products Anaplastic Thyroid Cancer- Unmet Needs Anaplastic Thyroid Cancer- Market Drivers and Barriers Anaplastic Thyroid Cancer- Future Perspectives and Conclusion Anaplastic Thyroid Cancer Analyst Views Anaplastic Thyroid Cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
an hour ago
- Globe and Mail
What Will Tesla's Robotaxi Service Look Like in the Future? CEO Elon Musk Envisions a Combination of Uber and Airbnb.
After years of speculation, Tesla (NASDAQ: TSLA) will soon launch its first batch of robotaxis in Austin, Texas, an event that will be closely monitored by the market. While Tesla at its core is an electric vehicle company, investors have run up the valuation of the stock by betting on future innovations like robotaxis and Tesla's planned rollout of humanoid Optimus robots. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Both could be massive new businesses that generate tons of new revenue. Looking specifically at robotaxis, Musk has grand plans. The billionaire foresees a business model that combines Uber and Airbnb. Let's take a look. Tesla owners could rent their vehicles to the fleet It's still early days, but if everything works out the way Musk hopes, Tesla will be able to launch a large ride-hailing fleet of driverless robotaxis that could potentially compete with the largest players like Uber. While Uber is not specifically building full self-driving (FSD) vehicles, it has positioned itself as a partner for autonomous companies and also forged several partnerships with big players like Waymo. Some have speculated that Tesla could potentially acquire or partner with Uber, although Musk has shut those rumors down, claiming there is no need. When videos recently surfaced of the first Tesla Model Ys beginning to map Austin, Musk said on X, "... these are unmodified Tesla cars coming straight from the factory, meaning that every Tesla coming out of our factories is capable of unsupervised self-driving!" The other big aspect that Musk wants to incorporate -- the Airbnb aspect -- is enabling Tesla owners to essentially rent out their vehicles to the fleet. Late last year, Gary Black, the renowned managing partner of The Future Fund, tweeted that Tesla owners could potentially earn $40,000 per year by renting out their Teslas to the robotaxi fleet. Black assumed that owners would charge $1 for each mile rented to the robotaxi fleet, take home 75% of the earnings, and also assumed 25 trips a day, with each trip six miles long on average. That would certainly be an intriguing proposition. Musk has also said that he thinks there could be hundreds of thousands of robotaxis in Tesla's fleet and on the road by late next year. Early days While the prospects of the robotaxi business are undoubtedly exciting, investors should probably temper their expectations for now. Musk recently announced that Tesla plans to roll out 10-20 robotaxis on June 22. Reports suggest the robotaxis will be driverless, but that there could be a human monitoring the vehicles remotely. Furthermore, the driverless Teslas will be geofenced to start, meaning they will only operate in certain parts of Austin. Initial media reports suggested the launch would be June 12, but Musk on X attributed the delay to Tesla being "super paranoid about safety." While I am not an expert on FSD, it strikes me as a little concerning that Tesla is pushing out a launch 10 days to once again ensure that everything is safe. I'm not suggesting the vehicles aren't safe, but rather that the launch could be pretty basic to begin with and that Musk's timeline for FSD is likely a bit ambitious. Ramping things up could take more time than expected. Additionally, as I've written about previously, I believe Tesla's current valuation likely factors in a significant amount of success from robotaxis and Optimus robots. Tesla already trades at 172 forward earnings. At the end of May, when Tesla traded at 180 times forward earnings, Black also noted on X that in the history of the stock market, no company with a $1 trillion market cap has ever traded at a forward P/E like that. At that kind of multiple, Black said Tesla's market cap should actually be bigger than Apple or Microsoft, which "seems insane," given these companies' massive total addressable markets, huge brands, and incredible cash-flow generating capabilities. This is something for investors to keep in mind. Don't miss this second chance at a potentially lucrative opportunity Ever feel like you missed the boat in buying the most successful stocks? Then you'll want to hear this. On rare occasions, our expert team of analysts issues a 'Double Down' stock recommendation for companies that they think are about to pop. If you're worried you've already missed your chance to invest, now is the best time to buy before it's too late. And the numbers speak for themselves: Nvidia: if you invested $1,000 when we doubled down in 2009, you'd have $368,190!* Apple: if you invested $1,000 when we doubled down in 2008, you'd have $37,294!* Netflix: if you invested $1,000 when we doubled down in 2004, you'd have $653,702!* Right now, we're issuing 'Double Down' alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon. See the 3 stocks » *Stock Advisor returns as of June 9, 2025 Bram Berkowitz has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Airbnb, Apple, Microsoft, Tesla, and Uber Technologies. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy.
